4th Jun 2021 19:21
Arix Bioscience PLC - the company which invests in biotech companies - Notes its portfolio company Harpoon Therapeutics Inc reported interim data from the ongoing dose-escalation portion of a phase 1/2a trial for its lead programme HPN424 in patients with metastatic castration-resistant prostate cancer. Harpoon notes that these interim data for HPN424 show early clinical activity, with a manageable safety profile.
Current stock price: 177.95 pence, down 0.6% on Friday
Year-to-date change: down 19%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
ARIX.L